



- (51) **International Patent Classification:**
A61P 39/02 (2006.01) *C07K 16/44* (2006.01)
- (21) **International Application Number:**
PCT/EP2012/055397
- (22) **International Filing Date:**
27 March 2012 (27.03.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/469,207 30 March 2011 (30.03.2011) US
- (71) **Applicant (for all designated States except US):**
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **VAN RYN, Joanne** [CA/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **CANADA, Keith** [US/US]; Boehringer Ingelheim Phar-

maceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877 (US). **COPENHAVER, Robert** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877 (US). **HAUEL, Norbert** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **LITZENBURGER, Tobias** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **SARKO, Christopher Ronald** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877 (US). **SINGH, Sanjaya** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877 (US). **WATERMAN, Alisa K.** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877 (US).

- (74) **Agents:** **HAMMANN ET AL., Heinz** et al.; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM,

[Continued on next page]

- (54) **Title:** ANTICOAGULANT ANTIDOTES

(57) **Abstract:** The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.




Figure 11



AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))